Browsing Tag
cell therapy
21 posts
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
Genenta Science partners with Anemocyte to unlock scalable LVV plasmid DNA supply for global cell and gene therapy developers
Find out how Genenta Science and Anemocyte are scaling off-the-shelf LVV plasmid DNA to revolutionize global gene and cell therapy manufacturing.
PHC Holdings signs exclusive deal to distribute MaxCyte ExPERT platform in Japan to advance non-viral cell engineering in CGT development
PHC Holdings signs exclusive deal to distribute MaxCyte’s ExPERT platform in Japan, expanding CGT manufacturing with scalable non-viral cell engineering
Portal Biotechnologies awarded $8m DARPA contract to create portable red blood cell therapy system for rapid field-based treatment
Portal Biotechnologies secures $8M DARPA contract to build a field-deployable red blood cell therapy device using mechanoporation technology.
Stem cell-based diabetes therapies at ADA 2025 show promise in eliminating insulin use for type 1 patients
VX-880 and immune-shielded stem cell islets show strong promise in clinical trials at ADA 2025, offering new possibilities in type 1 diabetes treatment.
AstraZeneca moves deeper into cell therapy with $1bn EsoBiotec acquisition
AstraZeneca’s $1 billion acquisition of EsoBiotec signals a major shift in cell therapy innovation. Find out how this deal could transform cancer treatment.
NLS Pharmaceutics advances Kadimastem merger with fundraising milestone
NLS Pharmaceutics Ltd., a Swiss biopharmaceutical company focused on therapies for rare central nervous system disorders, and Kadimastem…
Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial
Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute…
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase…
Gamma Biosciences to sell Mirus Bio to Merck KGaA for $600m in key biotech deal
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio…